PFK 158

Drug Profile

PFK 158

Alternative Names: ACT-PFK-158; PFK158

Latest Information Update: 13 Apr 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Louisville
  • Developer Advanced Cancer Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Glucose modulators; PFKFB3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 01 Mar 2014 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02044861)
  • 22 Jan 2014 Preclinical trials in Solid tumours in USA (IV)
  • 22 Jan 2014 Advanced Cancer Therapeutics plans a phase I trial for Solid tumours (second-line therapy or greater, late-stage disease) in USA (NCT02044861)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top